Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Liabilities (2016 - 2026)

Ani Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $899.7 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 5.11% to $899.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $899.7 million, a 5.11% increase, with the full-year FY2025 number at $899.7 million, up 5.11% from a year prior.
  • Total Liabilities hit $899.7 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $902.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for ANIP hit a ceiling of $902.3 million in Q3 2025 and a floor of $260.1 million in Q1 2021.
  • Historically, Total Liabilities has averaged $536.6 million across 5 years, with a median of $430.5 million in 2023.
  • Biggest five-year swings in Total Liabilities: dropped 7.45% in 2021 and later skyrocketed 100.25% in 2025.
  • Tracing ANIP's Total Liabilities over 5 years: stood at $412.9 million in 2021, then increased by 2.1% to $421.5 million in 2022, then rose by 6.0% to $446.8 million in 2023, then soared by 91.56% to $855.9 million in 2024, then grew by 5.11% to $899.7 million in 2025.
  • Business Quant data shows Total Liabilities for ANIP at $899.7 million in Q4 2025, $902.3 million in Q3 2025, and $881.4 million in Q2 2025.